KALA BIO, Inc. short interest in 2022
In 2022, KALA BIO, Inc.'s disclosed short interest ran from 5.57% of shares outstanding on 14 Jan 2022 to 6.66% on 15 Dec 2022, a change of +1.09 percentage points. The year's high was 10.99% on 15 Mar 2022 and its low 2.20% on 30 Sep 2022, averaging 5.11% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.26 days on 28 Feb 2022. Full history: KALA BIO, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 5.57% (14 Jan 2022)
- End of year
- 6.66% (15 Dec 2022)
- Change
- +1.09 pp
- High
- 10.99% (15 Mar 2022)
- Low
- 2.20% (30 Sep 2022)
- Average
- 5.11%
- Highest days to cover
- 9.26 (28 Feb 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 5.57% | 3.67 | |
| 31 Jan 2022 | 6.00% | 5.61 | |
| 15 Feb 2022 | 6.38% | 8.37 | |
| 28 Feb 2022 | 6.23% | 9.26 | |
| 15 Mar 2022 | 10.99% | 1.02 | |
| 31 Mar 2022 | 6.93% | 3.12 | 10-K filed, results (8-K) |
| 14 Apr 2022 | 6.13% | 5.51 | |
| 29 Apr 2022 | 6.22% | 8.01 | |
| 13 May 2022 | 7.22% | 5.46 | |
| 31 May 2022 | 6.88% | 1.49 | 10-Q filed, results (8-K) |
| 15 Jun 2022 | 4.86% | 1.74 | |
| 30 Jun 2022 | 2.97% | 1.00 | |
| 15 Jul 2022 | 2.82% | 1.70 | |
| 29 Jul 2022 | 2.51% | 2.45 | |
| 15 Aug 2022 | 2.82% | 1.64 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 2.87% | 1.00 | |
| 15 Sep 2022 | 2.53% | 2.33 | |
| 30 Sep 2022 | 2.20% | 4.63 | |
| 14 Oct 2022 | 2.26% | 4.26 | |
| 15 Nov 2022 | 5.04% | 1.00 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 6.32% | 1.00 | |
| 15 Dec 2022 | 6.66% | 2.60 |
See also: KALA BIO, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.